Teitur Trophics
Private Company
Funding information not available
Overview
Teitur Trophics is a private, clinical-stage biotech based in Copenhagen, Denmark, advancing novel therapeutics for neurodegenerative disorders. The company's core technology is a platform of cyclic peptides designed to address fundamental pathological hallmarks, with its lead program TT-P34 now in Phase I clinical trials for Parkinson's disease. Teitur operates as a pre-revenue therapeutics company, having spun out from Aarhus University, and is focused on achieving proof-of-concept in humans to validate its unique mechanism of action. The initiation of patient dosing marks a critical transition from preclinical research to clinical development.
Technology Platform
Platform of first-in-class cyclic peptides designed to restore lysosomal and mitochondrial function to address core pathologies in neurodegeneration.
Opportunities
Risk Factors
Competitive Landscape
Teitur competes in a crowded field of companies pursuing disease-modification for Parkinson's, including those targeting alpha-synuclein (e.g., Biogen, Roche), neuroinflammation, and mitochondrial function. Its differentiation lies in its cyclic peptide platform and simultaneous targeting of lysosomal and mitochondrial pathways, a less common dual approach.